Domestic innovative pharmaceutical companies have once again exposed a deep-water bomb.
On October 25th, Yin Min, the Chief Commercial Officer of BeiGene Greater China, a leading domestic innovative pharmaceutical company, was exposed by the media to be under investigation by regulatory agencies. The report stated that industry insiders confirmed the authenticity of this news to the media. After the news came out, BeiGene's stock price fluctuated slightly in the three major capital markets of the Science and Technology Innovation Board, Hong Kong Stock Exchange, and US Stock Exchange in the afternoon, with the largest decline in the Science and Technology Innovation Board market falling by more than 3%.
A reporter from Huaxia Times called the Investor Relations Department of BeiGene, but when the call was answered, it showed that the contact person was not available and needed to leave a message. However, it later showed that the phone mailbox was full and unable to leave a message. As of the time of publication, no external contacts related to BeiGene have responded to the authenticity of the information regarding Yin Min.
The day before, the specific date for the 2024 medical insurance negotiations was announced. In recent years, Yin Min, as the Chief Business Officer of BeiGene Greater China, has appeared multiple times at the medical insurance negotiations. It is unknown whether this well-known pharmaceutical executive will arrive as scheduled this time. Huaxia Times will track the relevant news as soon as possible.
According to official information, Yin Min officially joined BeiGene in January 2022. Prior to this, she had held multiple positions at multinational pharmaceutical companies AstraZeneca and Eli Lilly. She worked at AstraZeneca for nearly 15 years, moving through multiple business departments.